Clinical Report: Migaldendranib May Move the Needle in AMD, DME
Overview
Migaldendranib, a subcutaneous therapy, demonstrates safety and efficacy in reducing treatment burden for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The phase 2 study shows significant improvements in visual acuity and central subfield thickness with a reduced need for supplemental injections.
Background
The treatment of wet AMD and DME typically involves frequent intravitreal injections, which can be burdensome for patients. Innovations that reduce injection frequency while maintaining visual outcomes are critical in improving patient adherence and overall quality of life. Migaldendranib represents a potential shift in treatment paradigms by offering a subcutaneous option that targets both conditions with a single administration.
Data Highlights
| Condition | CST Decrease (µm) | BCVA Increase (letters) |
|---|---|---|
| Wet AMD | 45 | 3 |
| DME | 69 | 4.5 |
| Fellow Eye (Wet AMD) | 30 | 2.3 |
| Fellow Eye (DME) | Not significant | 2.3 |
Key Findings
- Migaldendranib is a subcutaneous tyrosine kinase inhibitor that targets VEGF.
- Patients experienced a significant reduction in treatment burden, with an average decrease of 80% for AMD and 74.45% for DME.
- Central subfield thickness (CST) decreased significantly in both wet AMD and DME patients.
- Visual acuity (BCVA) improved by an average of 3 letters in wet AMD and 4.5 letters in DME.
- Injection site reactions were mild and transient, occurring in 8.6% of patients.
- No liver or renal toxicity was observed, making it a safer alternative to previous treatments.
Clinical Implications
Migaldendranib offers a promising alternative to traditional intravitreal therapies, potentially reducing the frequency of injections and improving patient adherence. Its safety profile and efficacy in maintaining visual acuity make it a valuable option for managing wet AMD and DME.
Conclusion
The phase 2 results for migaldendranib indicate a significant advancement in the treatment of wet AMD and DME, with the potential to enhance patient care through reduced treatment burden and improved outcomes.
References
- Michael A. Singer, MD, Retinal Physician, 2025 -- Migaldendranib Demonstrates Efficacy in DME and nAMD
- Retinal Physician, 2022 -- Oral Drug Pipeline for Retinal Disease
- Ophthalmology, 2025 -- Current Clinical Guidance for AMD and DME
- Retinal Physician — Migaldendranib Demonstrates Efficacy in DME and nAMD
- Retinal Physician — SUBSPECIALTY NEWS
- ClinicalTrials.gov - Study Details for Migaldendranib
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
